Since Novartis' COX-2 inhibitor lumiracoxib [`Prexige'] has failed to demonstrate features differentiating it from the class leader celecoxib [`Celebrex; Pfizer/Pharmacia'], it could have limited market success

Author：  

Publisher： Adis International

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.403, 2003-01, pp. : 12-12

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The return on Pharmacia's COX-2 inhibitor product celecoxib [`Celebrex'] in Australia is far lower

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 321, 2001-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Pfizer-Pharmacia: the postmerger

By Wiggins Phillip  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 11, 2003-11 ,pp. : 1761-1763

Informa Healthcare

Access to resources Recommend Favorite

Lumiracoxib: new COX-2 inhibitor effective in osteoarthritis

By  

Inpharma, Vol. 1, Iss. 1403, 2003-01 ,pp. : 7-8

Adis International

Access to resources Recommend Favorite

Pfizer-Pharmacia: the smart fit for the future

By Wiggins W Phillip  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 1, 2003-01 ,pp. : 1-3

Informa Healthcare

Access to resources Recommend Favorite

Clinical pharmacology of celecoxib, a COX-2 selective inhibitor

By Antoniou Katerina   Malamas Michael   Drosos Alexandros A  

Expert Opinion on Pharmacotherapy, Vol. 8, Iss. 11, 2007-08 ,pp. : 1719-1732

Informa Healthcare

Access to resources Recommend Favorite